Matthew A. Lunning, DO | Authors

August 15, 2015

This article evaluates the most up-to-date peer-reviewed published work on the treatment of peripheral T-cell lymphoma, and offers a glimpse into the current upfront clinical trial landscape for patients affected by this uncommon disease.

April 15, 2014

Our heads hit the pillow later at night as the complexity of treating DLBCL increases, but we are well rested on account of the progress that is being made.

October 15, 2013

The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.